clinical trial · NCT04318405
Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).
Iron-Deficiency AnemiaIron-DeficiencyIron isomaltoside 1000
brief summary
Real-CHOICE - designed as a prospective, longitudinal, observational, non-interventional study - will investigate the attitude of patients and physicians towards IV (intravenous) iron therapy in general and IIM (iron isomaltoside 1000) treatment particularly before and after IIM treatment in iron deficient patients with or without anemia in the real-world clinical setting after commercial availability of this product in Switzerland.
started
Jul 10, 2020
primary completion
Nov 30, 2022
completion
Nov 30, 2022
last updated
Jul 19, 2023
official title
Iron Isomaltoside 1000 in Patients With Iron Deficiency or Iron Deficiency Anemia: a Multicentric, Prospective, Longitudinal, Observational Study in Switzerland.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol